Stereotactic ablative radiation therapy for pulmonary metastases from sarcoma primaries: A systematic review and meta-analysis of safety and efficacy.

IF 0.7 Q4 SURGERY

Journal of radiosurgery and SBRT Pub Date : 2025-01-01

Raj Singh, Robert Sierra, Casey Leimbach, Sidharth Iyer, Eric J Lehrer, Haley Perlow, Rituraj Upadhyay, Sung Jun Ma, Austin Sim, Emile Gogineni, Sujith Baliga, Daniel M Trifiletti, Joshua D Palmer, David J Konieczkowski, Jeremy Brownstein, Nicholas G Zaorzky

{"title":"Stereotactic ablative radiation therapy for pulmonary metastases from sarcoma primaries: A systematic review and meta-analysis of safety and efficacy.","authors":"Raj Singh, Robert Sierra, Casey Leimbach, Sidharth Iyer, Eric J Lehrer, Haley Perlow, Rituraj Upadhyay, Sung Jun Ma, Austin Sim, Emile Gogineni, Sujith Baliga, Daniel M Trifiletti, Joshua D Palmer, David J Konieczkowski, Jeremy Brownstein, Nicholas G Zaorzky","doi":"","DOIUrl":null,"url":null,"abstract":"Background: Though promising retrospective and prospective studies have reported on stereotactic ablative radiation therapy(SABR) for management of lung metastases from sarcoma primaries, they are limited by small patient numbers.Methods: The primary outcomes of interest were 1-year and 2-year local control (LC) and Grade 3-5 toxicities. Secondary outcomes were 1-year overall survival (OS) and 2-year OS. Weighted random effects meta-analyses using the DerSimonian and Laird methods were performed to calculate effect sizes.Results: Thirteen studies were identified with 533 patients and 940 lung metastases. The median prescription dose was 50 Gy (range: 48-60 Gy) in 5 fractions (range: 4-10). Following SABR, 1- and 2-year pooled LC rates were 97% (95% CI: 95-98%) and 91% (95% CI: 88-95%), respectively. Pooled 1- and 2-year OS rates were 85% (95% CI: 80-90%) and 68% (95% CI: 57-80%), respectively. The estimated incidence of Grade 3-5 toxicities following SABR was 0.1% (95% CI: 0-0.5%).Conclusion: SABR for sarcoma pulmonary metastases resulted in excellent LC with minimal toxicities.","PeriodicalId":16917,"journal":{"name":"Journal of radiosurgery and SBRT","volume":"9 3","pages":"215-226"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136686/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of radiosurgery and SBRT","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Though promising retrospective and prospective studies have reported on stereotactic ablative radiation therapy(SABR) for management of lung metastases from sarcoma primaries, they are limited by small patient numbers.

Methods: The primary outcomes of interest were 1-year and 2-year local control (LC) and Grade 3-5 toxicities. Secondary outcomes were 1-year overall survival (OS) and 2-year OS. Weighted random effects meta-analyses using the DerSimonian and Laird methods were performed to calculate effect sizes.

Results: Thirteen studies were identified with 533 patients and 940 lung metastases. The median prescription dose was 50 Gy (range: 48-60 Gy) in 5 fractions (range: 4-10). Following SABR, 1- and 2-year pooled LC rates were 97% (95% CI: 95-98%) and 91% (95% CI: 88-95%), respectively. Pooled 1- and 2-year OS rates were 85% (95% CI: 80-90%) and 68% (95% CI: 57-80%), respectively. The estimated incidence of Grade 3-5 toxicities following SABR was 0.1% (95% CI: 0-0.5%).

Conclusion: SABR for sarcoma pulmonary metastases resulted in excellent LC with minimal toxicities.

本刊更多论文

立体定向消融放疗治疗原发性肺转移性肉瘤：安全性和有效性的系统回顾和荟萃分析。

背景：虽然立体定向消融放疗（SABR）治疗原发性肉瘤肺转移的回顾性和前瞻性研究都有报道，但由于患者数量少，这些研究受到限制。方法：主要关注1年和2年局部对照（LC）和3-5级毒性。次要终点为1年总生存期（OS）和2年总生存期（OS）。加权随机效应荟萃分析采用DerSimonian和Laird方法计算效应量。结果：13项研究共纳入533例患者，940例肺转移灶。处方中位剂量为50 Gy（范围：48 ~ 60 Gy），分5次（范围：4 ~ 10次）。SABR后，1年和2年合并LC率分别为97% （95% CI: 95-98%）和91% （95% CI: 88-95%）。合并1年和2年的总生存率分别为85% （95% CI: 80-90%）和68% （95% CI: 57-80%）。SABR后3-5级毒性的估计发生率为0.1% （95% CI: 0-0.5%）。结论：SABR治疗肺转移性肉瘤疗效良好，毒性最小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of radiosurgery and SBRT SURGERY-

CiteScore

1.40

自引率

8.30%

发文量